세계 RS 바이러스(RSV) 백신 및 항체 파이프라인 시장 : 2028년까지 예측

출판:Daedal Research 출판년월:2022년04월

세계 RS 바이러스(RSV) 백신 및 항체 파이프라인 시장: 최종 사용자별, 유형별, 지역별, 크기별 분석 및 동향 – 2028년까지 예측

Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and forecast up to 2028

페이지수 113
가격
싱글 사용자 라이센스 USD2,250
2-5 사용자 라이센스 USD3,250
엔터프라이즈 라이센스 USD4,250
구성 영문조사보고서

리포트목차    주문/문의    납기/라이센스안내

Sample Request

RSV, or respiratory syncytial virus, is a common respiratory virus that causes mild, cold-like symptoms in both the upper and lower respiratory tracts. RSV can be harmful, especially in infants and the elderly, even though most individuals recover in a week or two. According to the Cleveland Clinic, RSV affects around 57,000 children under the age of five in the US each year. Despite massive global research efforts and decades of targeting RSV, there is still a significant unmet medical need.
RSV 또는 호흡기 세포융합 바이러스는 상부 및 하부 호흡기관 모두에서 경미하고 감기와 유사한 증상을 유발하는 일반적인 호흡기 바이러스입니다. RSV는 대부분의 개인이 1-2주 안에 회복되지만 특히 유아와 노인에게 해로울 수 있습니다. Cleveland Clinic에 따르면 RSV는 매년 미국에서 약 57,000명의 5세 미만 어린이에게 영향을 미칩니다. 대규모 글로벌 연구 노력과 수십 년 동안 RSV를 표적으로 삼았음에도 불구하고 여전히 충족되지 않은 의학적 요구가 상당합니다.

 

Potential therapeutics have had a difficult time proving a favorable safety profile or efficacy in the past. The numbers tell the story, there are currently no FDA-approved RSV medicines for adults and only two for at-risk newborns, even those have severe drawbacks, such as tight labelling, expensive pricing, limited antiviral activity, and worries about toxicity. However, the RSV vaccine development has made significant progress during the last ten years. The RSV vaccine and antibody market is expected to grow at a CAGR of 38.90% during the years 2024-2028.
잠재적인 치료제는 과거에 유리한 안전성 프로파일 또는 효능을 입증하는 데 어려움을 겪었습니다. 숫자는 현재 FDA 승인을 받은 성인용 RSV 의약품이 없고 위험에 처한 신생아를 위한 의약품은 2개뿐이며 엄격한 라벨링, 비싼 가격 책정, 제한된 항바이러스 활성 및 독성에 대한 우려와 같은 심각한 단점이 있음을 보여줍니다. 그러나 RSV 백신 개발은 지난 10년 동안 상당한 진전을 이루었습니다. RSV 백신 및 항체 시장은 2024-2028년 동안 38.90%의 CAGR로 성장할 것으로 예상됩니다.

 

As several vaccines and antibodies are near their last stage readouts, the commercialization and launch of some of these is expected by 2024. The estimates are done for the period, 2024 to 2028. Considering both the modalities (antibody and vaccine) targeting all three key age groups, the global RSV vaccine and antibody market is expected to be worth US$2.56 billion in 2024, rising to US$9.53 billion in 2028.

Market Segmentation Analysis:

By Type: The report provides the bifurcation of respiratory syncytial virus vaccine and antibody market into two segments on the basis of type: Vaccine and Antibody. In 2024, the vaccine segment is foreseen to lead the respiratory syncytial virus vaccine and antibody market, accounting for 67.5% share of the market as several vaccines candidates trials are near the last stage readouts and their launch is expected soon. Adult vaccination can also help in preventing RSV infection in children when a susceptible child is surrounded by vaccinated people, providing a localised herd immunity effect.

By End User: The report identifies two segments on the basis of end user: Adult, and Maternal And Pediatric. The adult segment is likely to dominate the respiratory syncytial virus vaccine and antibody market in 2024, with 59.08% share of the market. The rising incidence of RSV in older and immunocompromised adults has gained a lot of traction over the years, and several major players have begun adult vaccine and antibody trials, which is seen as a key factor in giving the adult segment a dominant share.

By Region: In the report, the global respiratory syncytial virus vaccine and antibody market is divided into three regions: The US, Europe, and ROW. The US is projected to dominate the market in 2024 by occupying almost half of the share of the global market. The most important factor driving the respiratory syncytial virus vaccine and antibody market in the US is rising prevalence of RSV. Moreover, presence of major players and good healthcare facilities in the region would boost the US respiratory syncytial virus vaccine and antibody market in the years to come. Europe respiratory syncytial virus vaccine and antibody market provides lucrative opportunities in the coming years. Various reasons such as improved healthcare infrastructure, changing demographic divion, an active government drive to track RSV seasons, and a well-established reimbursement system for hospitals, are expected to drive the growth of the market in Europe.

Global Respiratory Syncytial Virus Vaccine And Antibody Market Dynamics:

Growth Drivers: The global respiratory syncytial virus vaccine and antibody market is likely to be driven by the rising prevalence of respiratory syncytial virus highlighting the greater unmet need for RSV vaccines. Furthermore, the factors such as rapid urbanization, increasing geriatric population, increase in healthcare expenditure, growing instances of RSV among kids, and favorable government support have constantly supported the development of vaccines and antibodies in the past years, propelling the growth of the market.

Challenges: Some challenges are also impeding the growth of the market such as high cost of vaccine development and inequitable access to vaccines. Pharmaceutical companies have had substantial difficulties in developing medications to treat RSV, as seen by the approval of only one product, Synagis, in the last two decades. In the late stages of development, a huge number of monoclonal antibody and vaccine candidates have failed to attain the needed efficacy and have suffered serious setbacks.

Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as use of artificial intelligence (AI) in vaccine and drug design, technological advancements in vaccine administration and competitive pipeline. The use of monoclonal antibodies in neonates to enhance passive immunization is one of the key techniques being researched by pharmaceuticals in their fight against RSV. The pipeline products outperform Synagis and the other technique of vaccination pregnant mothers to provide infants with passive immunization.

Impact Analysis of COVID-19 and Way Forward:

RSV epidemiology has changed substantially as a result of the COVID-19 pandemic. In fact, the RSV season in 2020 was short or non-existent in many areas, with only a few cases. Trial recruitment had largely paused while numerous immunization protocols for COVID-19 were being developed. The RSV season in the US is usually assumed to begin in October and peak between late December and mid-February, however this has altered to a later date. The CDC has noticed that a recent rise in RSV cases, which is generally rarely seen in the summer, has drastically altered the RSV research environment. While the COVID-19 pandemic pushed vaccine development to the forefront, it also slowed clinical research in several therapeutic areas, such as respiratory syncytial virus (RSV).

The need for more structural transformation in the healthcare sector and vaccine development has been underlined by COVID-19. COVID-19 has made people aware about the underlined effects of cross contaminations and contagious diseases. As a result, consumers are becoming more cognizant of proper vaccination and antibodies. The increased awareness of vaccination is expected to drive the growth of RSV vaccine and antibody market during the post COVID period.

Competitive Landscape:

The global Respiratory syncytial virus vaccine and antibody market is concentrated. RSV (respiratory syncytial virus) has long been a vaccine target. Vaccines are finally making their way through late-stage testing, despite a number of high-profile trial failures over the years. RSV vaccines developed by Pfizer and GlaxoSmithKline are currently in late-stage testing. With its late-stage RSV program, Sanofi is adopting a different track. The company and its partner AstraZeneca are developing a preventive monoclonal antibody for infants, which they plan to submit for FDA clearance next year. Other vaccine and biotechnology companies, such as Bavarian Nordic and Moderna, are in the middle or early stages of RSV testing and are likely to gain a significant share of the market.

The key players of the global respiratory syncytial virus vaccine and antibody market are

Johnson & Johnson Inc.
Pfizer Inc.
GlaxoSmithKline
AstraZeneca Plc.
Merck & Co. Inc.
Sanofi
Bavarian Nordic
Moderna Inc.
Meissa Vaccines
Advaccine
Codagenix

The players of the market are focusing on inorganic growth by conducting RSV vaccine clinical trials in order to increase their market share and presence, as well as expanding their capabilities with broader offers to meet growing market demand. Collaborations and partnerships, innovative product releases, and expansions of manufacturing and distribution units are some of the primary strategies used by companies in global respiratory syncytial virus vaccine and antibody market.

Scope of the Report:

The report titled “Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and forecast up to 2028”, includes :

–An in-depth analysis of the global respiratory syncytial virus vaccine and antibody market by end user, by type, by region, etc.

–Market estimates and forecasts from 2024 to 2028 for effective decision making.

–The regional analysis of the respiratory syncytial virus vaccine and antibody market, including the following regions:

The US
Europe
ROW

–Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

–Provides an analysis of the COVID-19 impact on the global respiratory syncytial virus vaccine and antibody market.

–Assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall respiratory syncytial virus vaccine and antibody market has also been forecasted for the period 2024-2028, taking into consideration the growth drivers, and the current and future trends.

–Evaluation of the potential role and efficacy of respiratory syncytial virus vaccines and antibodies to improve the market status.

–Identification of new technological developments, R&D activities, and product launches occuring in the respiratory syncytial virus vaccine and antibody market.

–In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

–The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

–The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.


목차

1. Executive Summary

2. Introduction

2.1 Respiratory Syncytial Virus (RSV) Vaccine & Antibody: An Overview

2.1.1 Antigenic Subtypes Of Respiratory Syncytial Virus
2.1.2 What Went Wrong With Previous RSV Vaccines?
2.1.3 Pre F Protein & It’s Increasing Use in RSV Vaccines

2.2 RSV Vaccine & Antibody (RSV) Segmentation: An Overview
2.2.1 Respiratory Syncytial Virus Vaccine & Antibody Segmentation

3. Global Market Analysis

3.1 Global RSV Vaccine And Antibody Market: An Analysis

3.1.1 Global RSV Vaccine And Antibody Market by Value
3.1.2 Global RSV Vaccine And Antibody Market by End User (Adult and Maternal and Pediatric)
3.1.3 Global RSV Vaccine And Antibody Market by Type (RSV Vaccine and RSV Antibody )
3.1.4 Global RSV Vaccine And Antibody Market by Region (The US, Europe, and ROW)

3.2 Global RSV Vaccine And Antibody Market: End User Analysis

3.2.1 Global Adult RSV Vaccine And Antibody Market by Value
3.2.2 Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value

3.3 Global RSV Vaccine And Antibody Market: Type Analysis

3.3.1 Global RSV Vaccine Market by Value
3.3.2 Global RSV Vaccine Market by End User (Adult and Maternal and Pediatric)
3.3.3 Global RSV Vaccine Market by Region (The US, Europe, and ROW)
3.3.4 Global RSV Antibody Market by Value
3.3.5 Global RSV Antibody Market by Region (The US, Europe, and ROW)

3.4 Global RSV Vaccine Market: End User Analysis

3.4.1 Global Adult RSV Vaccine Market by Value
3.4.2 Global Maternal & Pediatric RSV Vaccine Market by Value

4. Regional Market Analysis

4.1 The US RSV Vaccine And Antibody Market: An Analysis

4.1.1 The US RSV Vaccine And Antibody Market by Value
4.1.2 The US RSV Vaccine Market by Value
4.1.3 The US RSV Vaccine Market by End User (Adult and Maternal and Pediatric)
4.1.4 The US Adult RSV Vaccine Market by Value
4.1.5 The US Adult RSV Vaccine Market by Product Type
4.1.6 The US Maternal & Pediatric RSV Vaccine Market by Value
4.1.7 The US Maternal & Pediatric RSV Vaccine Market by Product Type
4.1.8 The US RSV Antibody Market by Value
4.1.9 The US RSV Antibody Market by Product Type

4.2 Europe RSV Vaccine And Antibody Market: An Analysis

4.2.1 Europe RSV Vaccine And Antibody Market by Value
4.2.2 Europe RSV Vaccine Market by Value
4.2.3 Europe RSV Vaccine Market by End User (Adult and Maternal and Pediatric)
4.2.4 Europe Adult RSV Vaccine Market by Value
4.2.5 Europe Adult RSV Vaccine Market by Product Type
4.2.6 Europe Maternal & Pediatric RSV Vaccine Market by Value
4.2.7 Europe Maternal & Pediatric RSV Vaccine Market by Product Type
4.2.8 Europe RSV Antibody Market by Value
4.2.9 Europe RSV Antibody Market by Product Type

4.3 ROW RSV Vaccine And Antibody Market: An Analysis

4.3.1 ROW RSV Vaccine And Antibody Market by Value
4.3.2 ROW RSV Vaccine Market by Value
4.3.3 ROW RSV Vaccine Market by End User (Adult and Maternal and Pediatric)
4.3.4 ROW Adult RSV Vaccine Market by Value
4.3.5 ROW Adult RSV Vaccine Market by Product Type
4.3.6 ROW Maternal & Pediatric RSV Vaccine Market by Value
4.3.7 ROW Maternal & Pediatric RSV Vaccine Market by Product Type
4.3.8 ROW RSV Antibody Market by Value
4.3.9 ROW RSV Antibody Market by Product Type

5. Impact of COVID-19

5.1 Impact of COVID-19

5.1.1 Impact of COVID-19 on Healthcare
5.1.2 Impact of COVID-19 Restrictions on RSV Transmission
5.1.3 Impact of COVID-19 on RSV Vaccine and Antibody Market

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Rapid Urbanization
6.1.2 Increasing Geriatric Population
6.1.3 Increasing Healthcare Expenditure
6.1.4 Rising Prevalence of Respiratory Syncytial Virus
6.1.5 Greater Unmet Need
6.1.6 Growing Instances of RSV Among Infants
6.1.7 Favorable Government Support

6.2 Challenges
6.2.1 High Cost of Vaccine Development
6.2.2 Inequitable Access to Vaccines

6.3 Market Trends
6.3.1 Use of Artificial Intelligence (AI) in Vaccine and Drug Design
6.3.2 Technological Advancements in Vaccine Administration
6.3.3 Competitive Pipeline

7. Competitive Landscape

7.1 Global RSV Vaccine And Antibody Market: Vaccine & Antibody Candidates
7.2 Global RSV Vaccine And Antibody Players By Market Share
7.3 Global RSV Vaccine And Antibody Market: Current Landscape

8. Company Profiles

8.1 Johnson & Johnson Inc.
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategies

8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies

8.3 AstraZeneca Plc
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategies

8.4 GlaxoSmithKline
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategies

8.5 Merck & Co., Inc.
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategies

8.6 Sanofi
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategies

8.7 Bavarian Nordic
8.7.1 Business Overview
8.7.2 Operating Segments
8.7.3 Business Strategies

8.8 Moderna Inc.
8.8.1 Business Overview
8.8.2 Business Strategies

8.9 Meissa Vaccines
8.9.1 Business Overview
8.9.2 Business Strategies

8.10 Advaccine
8.10.1 Business Overview
8.10.2 Business Strategies

8.11 Codagenix
8.11.1 Business Overview
8.11.2 Business Strategies

List of Figures

Figure 1: Antigenic Subtypes Of Respiratory Syncytial Virus
Figure 2: What went wrong with previous RSV vaccines?
Figure 3: Pre F Protein & It’s Increasing Use in RSV Vaccines
Figure 4: Respiratory Syncytial Virus Vaccine & Antibody Segmentation
Figure 5: Global RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 6: Global RSV Vaccine And Antibody Market by End User; 2024 & 2028 (Percentage, %)
Figure 7: Global RSV Vaccine And Antibody Market by Type; 2024 & 2028 (Percentage, %)
Figure 8: Global RSV Vaccine And Antibody Market by Region; 2024 (Percentage, %)
Figure 9: Global Adult RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 10: Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 11: Global RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 12: Global RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 13: Global RSV Vaccine Market by Region; 2024 (Percentage, %)
Figure 14: Global RSV Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 15: Global RSV Antibody Market by Region; 2024 (Percentage, %)
Figure 16: Global Adult RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 17: Global Maternal & Pediatric RSV Vaccine Market by Value; 2024-2028 (US$ Million)
Figure 18: The US RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 19: The US RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 20: The US RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 21: The US Adult RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 22: The US Adult RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 23: The US Maternal & Pediatric RSV Vaccine Market by Value; 2024-2028 (US$ Million)
Figure 24: The US Maternal & Pediatric RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 25: The US RSV Antibody Market by Value; 2024-2028 (US$ Million)
Figure 26: The US RSV Antibody Market by Product Type; 2024-2028 (US$ Million)
Figure 27: Europe RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 28: Europe RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 29: Europe RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 30: Europe Adult RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 31: Europe Adult RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 32: Europe Maternal & Pediatric RSV Vaccine Market by Value; 2024-2028 (US$ Million)
Figure 33: Europe Maternal & Pediatric RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 34: Europe RSV Antibody Market by Value; 2024-2028 (US$ Million)
Figure 35: Europe RSV Antibody Market by Product Type; 2024-2028 (US$ Million)
Figure 36: ROW RSV Vaccine And Antibody Market by Value; 2024-2028 (US$ Billion)
Figure 37: ROW RSV Vaccine Market by Value; 2024-2028 (US$ Billion)
Figure 38: ROW RSV Vaccine Market by End User; 2024 (Percentage, %)
Figure 39: ROW Adult RSV Vaccine Market by Value; 2024-2028 (US$ Million)
Figure 40: ROW Adult RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 41: ROW Maternal & Pediatric RSV Vaccine Market by Value; 2024-2028 (US$ Million)
Figure 42: ROW Maternal & Pediatric RSV Vaccine Market by Product Type; 2024-2028 (US$ Million)
Figure 43: ROW RSV Antibody Market by Value; 2024-2028 (US$ Million)
Figure 44: ROW RSV Antibody Market by Product Type; 2024-2028 (US$ Million)
Figure 45: Global Urban Population as a Share of Total Population; 2014-2020 (Percentage, %)
Figure 46: Global Population by Age Group; 2016-2020 (Million)
Figure 47: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2021 (Percentage, %)
Figure 48: Global Market Size for Artificial Intelligence in Healthcare; 2016-2025 (US $Billion)
Figure 49: Johnson & Johnson Inc. Sales to Customers by Segments; 2021 (Percentage, %)
Figure 50: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
Figure 51: AstraZeneca Total Revenue by Disease Areas; 2021 (Percentage, %)
Figure 52: GlaxoSmithKline Turnover by Segments; 2021 (Percentage, %)
Figure 53: Merck & Co., Inc. Sales by Segments; 2021 (Percentage, %)
Figure 54: Sanofi Net Sales by Segments; 2021 (Percentage, %)
Figure 55: Bavarian Nordic Revenue by Products; 2021 (Percentage, %)
Table 1: RSV V/S COVID-19
Table 2: Global RSV Vaccine And Antibody Pipeline Snapshot
Table 3: Global RSV Vaccine And Antibody Players By Market Share
Table 4: Global RSV Vaccine And Antibody Market: Current Landscape


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com